CJC-1295 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-17. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Charles Herbert Best (February 27, 1899 – March 31, 1978), was an American-Canadian medical scientist and one of the co-discoverers of insulin with Frederick Banting. He served as the chair of the Banting and Best Department of Medical Research at the University of Toronto and was further involved in research concerning choline and heparin.
Le Cake-Walk infernal, sold in the United States as The Cake Walk Infernal and in Britain as The Infernal Cake Walk, is a 1903 French silent trick film by Georges Méliès. It was sold by Méliès's Star Film Company and is numbered 453–457 in its catalogues. The film features the cakewalk, which was booming in popularity in 1903. Méliès appears in the film as Pluto/Satan and as the grotesque dancing demon. This rhythm-dependent film was probably filmed to piano accompaniment in the studio. Special effects in the film were worked with trapdoors, stage machinery, pyrotechnics, substitution splices, and multiple exposures. The Infernal Cake Walk features several examples of elements reused from, or later reused in, other films also made by Méliès. The demon masks in the film were originally made for Méliès's A Trip to the Moon (1902), where they are worn by the Selenites (Moon dwellers); similarly, the effect of dancing limbs had previously been used in Dislocation Extraordinary (1901). Conversely, Méliès reused The Infernal Cakewalk's grotto set in his later film The Damnation of Faust (1903), and recycled the will-o'-the-wisp effect in The Infernal Cauldron (1903).
== Structure == The structure of KLB was established by a combination of mass-spectrometry and NMR methods. Klebsazolicin is 23-aminoacid long peptide, containing four azoles (3 thiazoles and an oxazole) and an N-terminal lactamidine ring. The latter is formed by a linkage between two N-terminal amino acids (serine and glutamine) and is absolutely essential for bioactivity.
=== Aviptadil === In the wake of the COVID-19 pandemic, scientists at Relief conducted initial studies into the efficacy of RLF-100 in treating severe COVID-19 patients. In June 2020, the U.S. Food and Drug Administration granted fast-track designation to RLF-100 for treatment of respiratory distress in COVID-19. In September 2020, Relief partnered with US-Israeli firm NRX Pharmaceuticals (formerly NeuroRx Inc) for the co-development of the drug and the co-ordination of US trials. In April 2021, a reformulated version of aviptadil, known as Zyesami, was included in a National Institutes of Health (NIH) sponsored Phase 3 trial with the aim of testing aviptadil against remdesivir. In May 2021, NRX submitted a request for an Emergency Use Authorization (EUA) to the US FDA for aviptadil's use in patients in intensive care. On 7 October 2021 Relief Therapeutics filed a lawsuit against NRX Pharmaceuticals and its CEO Dr. Jonathan Javitt in the Supreme Court of the State of New York, citing multiple alleged breaches of the collaboration agreement signed by the two companies for the co-development of aviptadil. On 4 November 2021 the FDA declined EUA for the drug, but committed to working with NRX to further develop it. On 29 November 2021, NRX announced that data analysis from the NIH-sponsored Phase 3 trial showed a fourfold increase in survival at 60 days for patients administered with Zyesami (Aviptadil) vs those who received placebo.
Sources: en.wikipedia.org
Alkyl amines characteristically feature tetrahedral nitrogen centers. C-N-C and C-N-H angles are near 109°. C-N distances are slightly shorter than C-C distances. The energy barrier for the nitrogen inversion of the stereocenter is about 7 kcal/mol for a trialkylamine. The interconversion has been compared to the inversion of an open umbrella into a strong wind. Amines of the type NHRR' and NRR′R″ are chiral: the nitrogen center bears four substituents counting the lone pair. Because of the low barrier to inversion, amines of the type NHRR' cannot be obtained in optical purity. For chiral tertiary amines, NRR′R″ can only be resolved when the R, R', and R″ groups are constrained in cyclic structures such as N-substituted aziridines (quaternary ammonium salts are resolvable).
Afropop Worldwide's public radio program on Zulu Music, "The Zulu Factor" People of Africa, Zulu marriage explained An article on Piet Retief, including his interactions with Dingane History section of the official page for the Zululand region Archived 26 September 2008 at the Wayback Machine Human Rights Watch report on KwaZulu, just before the 1994 elections – This includes detailed, well-referenced, sections on recent Zulu history.
== Nomenclature == In 1997, Jamie I. Fletcher and his research associates introduced new nomenclature for classifying Australian funnel web spider toxins. They suggested replacing the trivial name 'versutoxin' with delta-hexatoxin-Hv1 instead. The delta represents the main biological activity of the neurotoxin; inhibiting sodium channels. In more recent research, atracotoxins have been rebranded as hexatoxins, but the two are still used interchangeably along with the abbreviations HXTX and ACTX. Delta and Hv1 are still used to specify the neurotoxic peptide versutoxin.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.